$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn

$vtgn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000143774924003916 Filed on February 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$197.3K	$411.4K
YoY Change	12.1%	129.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.120M	$3.758M
YoY Change	33.87%	21.53%
% of Gross Profit
Research & Development	$7.437M	$4.538M
YoY Change	-20.35%	-33.8%
% of Gross Profit
Depreciation & Amortization	$32.50K	$34.50K
YoY Change	-2.4%	12.75%
% of Gross Profit
Operating Expenses	$11.56M	$8.295M
YoY Change	-6.92%	-16.6%
Operating Profit		-$7.884M
YoY Change		-19.28%
Interest Expense	$1.527M	$1.534M
YoY Change	12116.8%	28847.17%
% of Operating Profit
Other Income/Expense, Net	$312.0K
YoY Change
Pretax Income	-$9.520M	-$6.350M
YoY Change	-22.13%	-34.95%
Income Tax	$1.500K	$0.00
% Of Pretax Income
Net Earnings	-$9.521M	-$6.350M
YoY Change	-22.13%	-34.95%
Net Earnings / Revenue	-4825.85%	-1543.46%
Basic Earnings Per Share		-$0.22
Diluted Earnings Per Share	-$0.31	-$0.22
COMMON SHARES
Basic Shares Outstanding	27.03M	27.02M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.2M	$126.6M
YoY Change	616.25%	405.48%
Cash & Equivalents	$119.2M	$126.6M
Short-Term Investments	$0.00
Other Short-Term Assets	$1.506M	$1.555M
YoY Change	153.07%	79.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$120.7M	$128.1M
YoY Change	589.26%	391.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$435.0K	$445.1K
YoY Change	-14.25%	-17.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$726.0K	$575.3K
YoY Change	-10.83%	-22.93%
Total Long-Term Assets	$2.981M	$2.954M
YoY Change	-16.77%	-19.1%
TOTAL ASSETS
Total Short-Term Assets	$120.7M	$128.1M
Total Long-Term Assets	$2.981M	$2.954M
Total Assets	$123.7M	$131.1M
YoY Change	486.33%	341.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.547M	$1.737M
YoY Change	-37.45%	8.64%
Accrued Expenses	$2.235M	$129.3K
YoY Change	183.85%	-88.09%
Deferred Revenue	$791.0K	$1.763M
YoY Change	10.74%	147.48%
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due		$1.900K
YoY Change		18.75%
Total Short-Term Liabilities	$5.123M	$4.165M
YoY Change	12.16%	-2.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$6.000K
YoY Change	-100.0%	-24.05%
Other Long-Term Liabilities	$4.244M	$3.613M
YoY Change	-4.29%	-23.77%
Total Long-Term Liabilities	$4.244M	$3.619M
YoY Change	-4.45%	-23.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.123M	$4.165M
Total Long-Term Liabilities	$4.244M	$3.619M
Total Liabilities	$9.367M	$7.783M
YoY Change	3.97%	-13.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$356.2M	-$346.7M
YoY Change	8.96%	10.2%
Common Stock	$27.00K	$27.00K
YoY Change	269.86%	-86.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$114.3M	$123.3M
YoY Change
Total Liabilities & Shareholders Equity	$123.7M	$131.1M
YoY Change	486.33%	341.18%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$9.521M	-$6.350M
YoY Change	-22.13%	-34.95%
Depreciation, Depletion And Amortization	$32.50K	$34.50K
YoY Change	-2.4%	12.75%
Cash From Operating Activities	-$7.197M	-$4.536M
YoY Change	-3.69%	-54.34%
INVESTING ACTIVITIES
Capital Expenditures	$28.70K	$32.30K
YoY Change		158.4%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$28.70K	-$32.30K
YoY Change	-94.57%	158.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-167.8K	93.52M
YoY Change	-57.91%	-30852.98%
NET CHANGE
Cash From Operating Activities	-7.197M	-4.536M
Cash From Investing Activities	-28.70K	-32.30K
Cash From Financing Activities	-167.8K	93.52M
Net Change In Cash	-7.394M	88.95M
YoY Change	-11.98%	-967.83%
FREE CASH FLOW
Cash From Operating Activities	-$7.197M	-$4.536M
Capital Expenditures	$28.70K	$32.30K
Free Cash Flow	-$7.226M	-$4.568M
YoY Change	-3.3%	-54.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001411685
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37761
	dei	Entity Registrant Name EntityRegistrantName	VISTAGEN THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5093315
	dei	Entity Address Address Line1 EntityAddressAddressLine1	343 Allerton Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	577-3600
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	VTGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27025209
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7300	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	473918200	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	342892500	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126559200	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16637600	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1480300	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	802700	usd
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	74500	usd
CY2023Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	67100	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	128114000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	17507400	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	445100	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	507300	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1933600	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2260300	usd
CY2023Q4	vtgn	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	325700	usd
CY2023Q1	vtgn	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	495700	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	148700	usd
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	217600	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	100900	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	100900	usd
CY2023Q4	us-gaap	Assets Assets	131068000	usd
CY2023Q1	us-gaap	Assets Assets	21089200	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1737000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2473100	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	129300	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	787400	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1762800	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	714300	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	533500	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485600	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1900	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1700	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4164500	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4567400	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1899400	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2314600	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1713300	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2119800	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7400	usd
CY2023Q4	us-gaap	Liabilities Liabilities	7783200	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9009200	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27029731
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7315583
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4522
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4522
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3968100	usd
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3968100	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-346692300	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-326851700	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	123284800	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12080000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131068000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21089200	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	411400	usd
CY2022Q4	vtgn	Revenue From Contract With Customer Including Assessed Tax Derecognized RevenueFromContractWithCustomerIncludingAssessedTaxDerecognized	-179600	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	866700	usd
	vtgn	Revenue From Contract With Customer Including Assessed Tax Derecognized RevenueFromContractWithCustomerIncludingAssessedTaxDerecognized	402900	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	411400	usd
CY2022Q4	vtgn	Revenue From Contract With Customer Including Assessed Tax Derecognized RevenueFromContractWithCustomerIncludingAssessedTaxDerecognized	-179600	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	866700	usd
	vtgn	Revenue From Contract With Customer Including Assessed Tax Derecognized RevenueFromContractWithCustomerIncludingAssessedTaxDerecognized	402900	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4537600	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6854000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12585400	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35039800	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3757800	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3092100	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9943300	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11586200	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	8295400	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	9946100	usd
	us-gaap	Operating Expenses OperatingExpenses	22528700	usd
	us-gaap	Operating Expenses OperatingExpenses	46626000	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7884000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9766500	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21662000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47028900	usd
CY2023Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1534200	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5300	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1823900	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	13700	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6349800	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9761200	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19838100	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47015200	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2500	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5500	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6349800	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-9761200	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19840600	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47020700	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.82
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29388085
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6894603
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15632451
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6891641
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	64715300	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	956900	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	56100	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-19776300	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	46052000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1031800	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4400	usd
CY2022Q3	vtgn	Stock Issued During Period Value Cashless Stock Options Exercised StockIssuedDuringPeriodValueCashlessStockOptionsExercised	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-17483200	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	29605000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	746300	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7000	usd
CY2022Q4	vtgn	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	77400	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-9761200	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	20674500	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12080000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	569100	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4200	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1098800	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6903100	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6849000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	583700	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34800200	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6587700	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	35645200	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	506700	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3700	usd
CY2023Q4	vtgn	Stock Issued During Period Value Public Offering StockIssuedDuringPeriodValuePublicOffering	93479000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6349800	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	123284800	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19840600	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47020700	usd
	vtgn	Depreciation Depletion And Amortization Excluding Amortization Of Operating Lease Assets DepreciationDepletionAndAmortizationExcludingAmortizationOfOperatingLeaseAssets	94500	usd
	vtgn	Depreciation Depletion And Amortization Excluding Amortization Of Operating Lease Assets DepreciationDepletionAndAmortizationExcludingAmortizationOfOperatingLeaseAssets	96200	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1659500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2734900	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	77400	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	327000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	297900	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-201900	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3037900	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-359000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-321500	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1394200	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1509500	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18615900	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42242400	usd
	vtgn	Payments To Acquire Laboratory And Other Equipment PaymentsToAcquireLaboratoryAndOtherEquipment	32300	usd
	vtgn	Payments To Acquire Laboratory And Other Equipment PaymentsToAcquireLaboratoryAndOtherEquipment	212000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32300	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-212000	usd
	vtgn	Proceeds From Issuance Of Common Stock And Option Exercises Net ProceedsFromIssuanceOfCommonStockAndOptionExercisesNet	0	usd
	vtgn	Proceeds From Issuance Of Common Stock And Option Exercises Net ProceedsFromIssuanceOfCommonStockAndOptionExercisesNet	104400	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	93517200	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1200	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	984800	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	720500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128569800	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-643600	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	109921600	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43098000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16637600	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	68135300	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126559200	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25037300	usd
	vtgn	Insurance Premiums Settled Issuing Note Payable InsurancePremiumsSettledIssuingNotePayable	879500	usd
	vtgn	Insurance Premiums Settled Issuing Note Payable InsurancePremiumsSettledIssuingNotePayable	1139700	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17900	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	10600	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2.</b> <b>Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (<i>U.S.</i> <i>GAAP</i>) applicable to interim financial information and pursuant to the instructions of the Securities and Exchange Commission (<i>SEC</i>) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Further, the results of our operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or the full fiscal year. In the opinion of management, all normal and recurring adjustments considered necessary for a fair presentation have been included. The condensed consolidated balance sheet at March 31, 2023, has been derived from our audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The report of our independent auditors included an explanatory paragraph in their opinion on our consolidated financial statements as of and for the fiscal year ended March 31, 2023, that states that our ongoing losses raised substantial doubt about our ability to continue as a going concern. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the accompanying notes should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 (our <i>Annual Report</i>).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Vistagen and its subsidiaries. All intercompany accounts and transactions have been eliminated.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On June 6, 2023, we implemented a stockholder-approved one-for-thirty (1-for-30) reverse split of our common stock (the <i>Reverse Stock Split</i>). All share and per share data for all periods presented in the accompanying condensed consolidated financial statements and related disclosures in this Report have been adjusted retrospectively to reflect the Reverse Stock Split. Refer to Note 5, <i>Capital Stock</i>, for additional information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include those relating to revenue recognition, share-based compensation, right-of-use assets and lease liabilities and assumptions that have been used historically to value warrants and warrant modifications. Actual results could differ from those estimates. Changes in estimates are reflected in the reported results in the period in which they become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have incurred significant losses and negative cash flows from operations since inception. As of December 31, 2023, we had an accumulated deficit of $346.7 million. We expect that operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of $126.6 million as of December 31, 2023 will be sufficient to fund operating expenses and capital requirements for more than 12 months from the date the unaudited condensed consolidated financial statements are issued.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There were no significant updates not already disclosed in the Company’s audited consolidated financial statements for the years ended March 31, 2023, and 2022, to the recently issued accounting standards for the nine months ended December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include those relating to revenue recognition, share-based compensation, right-of-use assets and lease liabilities and assumptions that have been used historically to value warrants and warrant modifications. Actual results could differ from those estimates. Changes in estimates are reflected in the reported results in the period in which they become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-346700000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126600000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3577240
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.38
CY2023Q4	vtgn	Proceeds From Sale Of Securities Net Of Expenses ProceedsFromSaleOfSecuritiesNetOfExpenses	93500000	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	506700	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	746300	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1659500	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2734900	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21334294
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	832184

Files In Submission

Name	View Source	Status
0001437749-24-003916-index-headers.html	Edgar Link	pending
0001437749-24-003916-index.html	Edgar Link	pending
0001437749-24-003916.txt	Edgar Link	pending
0001437749-24-003916-xbrl.zip	Edgar Link	pending
ex_622478.htm	Edgar Link	pending
ex_622479.htm	Edgar Link	pending
ex_622480.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtgn-20231231.xsd	Edgar Link	pending
vtgn20231231_10q.htm	Edgar Link	pending
vtgn-20231231_def.xml	Edgar Link	unprocessable
vtgn-20231231_lab.xml	Edgar Link	unprocessable
vtgn-20231231_pre.xml	Edgar Link	unprocessable
vtgn20231231_10q_htm.xml	Edgar Link	completed
vtgn-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn

2024 Q1 Form 10-Q Financial Statement

#000143774924003916 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTGN Vistagen Therapeutics, Inc. Stock $vtgn

2024 Q1 Form 10-Q Financial Statement

#000143774924003916 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn